Copyright © Inderes 2011 - present. All rights reserved.

Biohit

2.31

 

EUR

 

-1.28 %

Corporate customer

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

4,738 following
Compare
-1.28%
-0.43%
+5.48%
+15.5%
+22.55%
+20.31%
+22.22%
-32.26%
-55.58%

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

Read more
Market cap
35.07M EUR
Turnover
69.11K EUR
P/E (adj.) (24e)
18.26
EV/EBIT (adj.) (24e)
14.08
P/B (24e)
3.04
EV/S (24e)
1.87
Dividend yield-% (24e)
-
Coverage
Recommendation
Accumulate
Target price
2.70 EUR
Updated
2024-08-08
Disclaimer
Latest research

Latest analysis report

Released: 2024-02-15

Latest extensive report

Released: 2023-07-02

Financial calendar
12/2
2025

Annual report '24

4/6
2025

General meeting '24

6/8
2025

Interim report Q2'25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Analyst Comment by
Antti Siltanen

Biohit is working on a new market launch and FDA approval

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3, but the company reports on its progress on the IR blog. The Q3 blog did not comment on progress against financial targets this time, so we expect the business to have continued to operate within the guidance range of 15-20% growth.

Biohit
Biohit H1'24 preview: Opening of a new strategy period
Analyst Comment by
Antti Siltanen

Biohit H1'24 preview: Opening of a new strategy period

Biohit will release its H1 report on Wednesday, August 7 at 9:30 am EEST. We expect the company to continue healthy growth during the first six months of the new strategy period. We expect the result to be at the level of the comparison period, as growth investments increase costs.

Biohit
Analyst Comment by
Antti Siltanen

Biohit strengthens R&D

On Friday, Biohit announced that it will change its organization to strengthen the company’s strategic and operational performance of R&D.

Biohit
Analyst Comment by
Antti Siltanen

Biohit's Q1 has gone according to plan

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3 but the company reports on its progress in the CEO’s blog. According to the blog, the implementation of the new strategy 2024-2028 started in Q1 as planned and on schedule.

Biohit
Forum discussions
Nedan är en analytikers skrivelse om Biohits senaste uppdateringar. Biohit that reports semi-annually does not publish business reviews for Q1 and Q3, but the company reports on its progress on the IR blog. The Q3 blog did not comment on progress against financial targets this time...
10/10/2024, 8:47 AM
by börsen84
2
I fredags meddelade Biohit att de kommer att förändra sin organisation för att stärka företagets strategiska och operativa prestation inom forskning och utveckling. Och här är en analytikers tankar om detta. Inderes Biohit strengthens R&D - Inderes On Friday, Biohit announced that...
6/17/2024, 10:43 AM
by börsen84
2
This article contains analyst comments regarding the first quarter. Inderes Biohit's Q1 has gone according to plan - Inderes Biohit that reports semi-annually does not publish business reviews for Q1 and Q3 but the company reports on its progress in the CEO’s blog. According to the...
4/9/2024, 2:12 PM
by börsen84
2
Säker avkastning och enorm tillväxt? Här är en färsk analys av ett intressant företag. Inderes Biohit: Growth measures taking effect - Inderes Biohit’s H2 exceeded our expectations in terms of growth and earnings were in line with our forecasts. Revenue growth was supported by positive...
2/16/2024, 11:54 PM
by börsen84
2
Fantastiskt, en ny och gratis samt högkvalitativ analys av Biohit. Inderes Biohit: From basics to growth mode - Inderes In its recent strategy update for 2024-2028, Biohit said it aims to achieve 15-20% annual growth with an EBIT target of at least 10% of revenue. Compared to our...
12/20/2023, 3:20 PM
by börsen84
2
Here is the analyst’s comments when Biohit announced its strategy and goals until 2028. Inderes — Connecting Investors and Companies Biohit renewed its strategy and targets until 2028 Biohit announced its renewed strategy for 2024-2028 on Wednesday. The main objective of the strategy...
11/23/2023, 3:30 PM
by börsen84
2
Här är analytikerns tankar om bland annat VD:s färska blogginlägg. Inderes — Connecting Investors and Companies Biohit’s Q3 has followed the stepping stones Biohit that reports semi-annually does not publish business reviews for Q1 and Q3 but the company reports on its progress in...
10/5/2023, 5:29 AM
by börsen84
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.